- Home
- LRFC vs BNR Comparison
LRFC vs BNR Comparison
Compare LRFC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- BNR
- Stock Information
- Founded
- LRFC 2013
- BNR 2014
- Country
- LRFC United States
- BNR China
- Employees
- LRFC N/A
- BNR N/A
- Industry
- LRFC Finance: Consumer Services
- BNR Medical Specialities
- Sector
- LRFC Finance
- BNR Health Care
- Exchange
- LRFC Nasdaq
- BNR Nasdaq
- Market Cap
- LRFC 68.2M
- BNR 72.4M
- IPO Year
- LRFC 2013
- BNR 2020
- Fundamental
- Price
- LRFC $23.92
- BNR $6.53
- Analyst Decision
- LRFC
- BNR
- Analyst Count
- LRFC 0
- BNR 0
- Target Price
- LRFC N/A
- BNR N/A
- AVG Volume (30 Days)
- LRFC 6.4K
- BNR 28.7K
- Earning Date
- LRFC 03-12-2025
- BNR 12-03-2024
- Dividend Yield
- LRFC 5.60%
- BNR N/A
- EPS Growth
- LRFC N/A
- BNR N/A
- EPS
- LRFC N/A
- BNR N/A
- Revenue
- LRFC $19,936,000.00
- BNR $72,832,704.00
- Revenue This Year
- LRFC $3.63
- BNR $52.90
- Revenue Next Year
- LRFC N/A
- BNR $48.35
- P/E Ratio
- LRFC N/A
- BNR N/A
- Revenue Growth
- LRFC N/A
- BNR N/A
- 52 Week Low
- LRFC $20.65
- BNR $2.62
- 52 Week High
- LRFC $26.00
- BNR $9.80
- Technical
- Relative Strength Index (RSI)
- LRFC 38.64
- BNR 49.85
- Support Level
- LRFC $23.78
- BNR $6.50
- Resistance Level
- LRFC $24.80
- BNR $7.39
- Average True Range (ATR)
- LRFC 0.51
- BNR 0.35
- MACD
- LRFC -0.07
- BNR -0.14
- Stochastic Oscillator
- LRFC 20.59
- BNR 25.41
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.